Knight Therapeutics Inc. is facing a notable decline in its stock price, reflecting investor concerns.
Knight Therapeutics Inc. (GUD.TO) is experiencing a downturn in its stock performance, dropping by 1.23% in today’s session. As the market reacts, investors are questioning the sustainability of the company’s recent gains and future prospects.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$915.52M
P/E
62.1x
52W high
$10.17
52W low
$5.66
1W change
+5.05%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 10.7% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.83
+10.7% Upside
Current Price
C$9.78
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.7%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.38 | C$9.27 – C$11.62 |
| 60 trading days | C$11.02 | C$9.39 – C$12.92 |
| 90 trading days | C$11.69 | C$9.62 – C$14.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Knight Therapeutics' performance and consider the implications of its recent stock decline on their portfolios.
Knight Therapeutics Inc. Market Cap at CA$915.5 Million
With a market cap of CA$915.5 million, Knight Therapeutics needs to show consistent revenue growth to justify its valuation.
Bull case
Despite today’s decline, Knight Therapeutics reported a solid Q1 2025 with a 2% revenue increase and a gross margin of 40%. This suggests there’s potential for recovery ahead.
Bear case
The 1.23% drop in stock price today raises concerns about the company's ability to keep up its momentum, especially with a high P/E ratio of 65.2, which might indicate overvaluation.
Stock Performance Overview
Advertisement
Knight Therapeutics Inc. saw its stock price decrease by 1.23% today, closing at CA$9.66. This decline follows a period of increased investor interest, raising questions about the sustainability of its recent gains. Investors are now left to ponder whether the company can maintain its growth trajectory amidst this downturn.
Financial Health Insights
The company's recent financial results, including a 2% revenue increase in Q1 2025, suggest some resilience. However, with a P/E ratio of 65.2, Knight Therapeutics may be viewed as overvalued, leading to increased scrutiny from investors. For more details on the company's performance, check out the Knight Therapeutics stock page.
Future Considerations
As Knight Therapeutics navigates this challenging period, investors should keep an eye on upcoming financial announcements and market reactions. The company's ability to adapt and respond to market pressures will be crucial in determining its future stock performance. For ongoing updates, visit the Knight Therapeutics stock page.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
